Philip Wolf, MD
Professor of Neurology
Location: Robinson, B-608
Dr. Philip A. Wolf received his medical degree from the State University of New York College of Medicine at Syracuse, and completed his residency at the Massachusetts General Hospital in Boston. He is Professor of Neurology, Research Professor of Medicine (Epidemiology and Preventive Medicine) at Boston University School of Medicine, and Professor of Public Health at Boston University School of Public Health. He was Co-PI on the Contract, The Framingham Study, Physical Examination, Testing and Surveillance awarded by the National Heart, Lung and Blood Institute (NHLBI) to Boston University School of Medicine from 1983 to 1989, and Principal Investigator from 1989 to 2000. Dr. Wolf continues as the Principal Investigator on the renewed contract, The Framingham Heart Study, 2001-2008.
For many years he was Chief of the Cerebrovascular Disease Section of the Department of Neurology and directed a number of international cooperative clinical studies of stroke: The NINDS Stroke Data Bank, The Ticlopidine-Aspirin Stroke Study (TASS), Boston Area Anticoagulation Trial in Atrial Fibrillation (BAATAF), North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Clopidogrel-Aspirin Prevention of Ischemic Events Study (CAPRIE).
Dr. Wolf has served on Executive Committees and Data Safety Monitoring Boards for a number of NIH and industry supported studies of Stroke including TASS, BAATAF, NASCET, BRAVO, VISP, TRENDS, WHI Stroke Study, and ProFESS. He serves on the monitoring boards of two NHLBI studies including the Cardiovascular Health Study and The Jackson Heart Study.
Dr. Wolf has served as active investigator in epidemiological studies of neurological diseases, principally stroke. His affiliation with The Framingham Heart Study spans more than 35 years and he is currently Principal Investigator of the NHLBI contract to conduct examinations and maintain surveillance of the Framingham Study cohorts.
In addition, Dr. Wolf is principal investigator of the AMRI, Genetics and Cognitive Precursors of AD and Dementia project, Epidemiology of Dementia Study, and the Precursors of Stroke Incidence and Prognosis Study, all NIH-funded research programs. The study of precursors and manifestations of stroke and dementia as well as outcome following stroke have been major aims of his research, which has been continuously funded since 1981.
Dr. Wolf, as PI of the Framingham Heart Study and of an NIA funded R01 grant studying AD & Dementia in the Framingham Study cohorts, participates in the scientific activities of the ADC. He is studying the role of vascular disease and vascular risk factors in cognitive decline, dementia, and specifically, AD. He is in charge of the active and successful brain donation program of Framingham Study subjects. Data generated by the systematic, quantitative examination of these brains by the ADC Neuropathology Core are related to life-style and medical variables collected over 35 years and to neuropsychological and quantitative brain MRI data within one year of death.
Dr. Wolf received the Jacob A. Javits Neuroscience Award by the Institute of Neurologic Diseases and Stroke. He was the first individual to receive the Humana Award for Excellence in Clinical Stroke of the Stroke Council of the American Heart Association. Dr. Wolf received the Mihara Award from the International Stroke Society and the American Stroke Association’s C. Miller Fisher Award.
Dr. Wolf is a member or fellow of numerous professional associations, including the American Academy of Neurology, American Neurologic Association, American Heart Association, American College of Epidemiology, American College of Preventive Medicine, American Epidemiological Society, and the council of Geriatric Cardiology. He is a fellow of the American Heart Association’s Stroke and Epidemiology Councils and served on the Executive Committee of both Councils.
Dr. Wolf previously served on the editorial board of the journal Stroke. He is author of more than 200 peer-reviewed papers and one of five Editors of the 4th Edition of the textbook Stroke – Pathophysiology, Diagnosis, and Management (2005).
For a full list of publications click here.
Dufouil C, Beiser AS, McClure LA, Wolf PA, Tzourio C, Howard VJ, Westwood AJ, Himali JJ, Sullivan LM, Aparicio HJ, Kelly-Hayes M, Ritchie K, Kase CS, Pikula A, Romero JR, D’Agostino RB, Samieri C, Vasan RS, Chêne G, Howard G, Seshadri S. A Revised Framingham Stroke Risk Profile to Reflect Temporal Trends. Circulation. 2017 Feb 03. PMID: 28159800.
Romero JR, Preis SR, Beiser A, Himali JJ, Shoamanesh A, Wolf PA, Kase CS, Ramachandran VS, DeCarli C, Seshadri S. Cerebral Microbleeds as Predictors of Mortality: The Framingham Heart Study. Stroke. 2017 Jan 31. PMID: 28143923.
Lubitz SA, Yin X, McManus DD, Weng LC, Aparicio HJ, Walkey AJ, Rafael Romero J, Kase CS, Ellinor PT, Wolf PA, Seshadri S, Benjamin EJ. Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study. Stroke. 2017 Feb; 48(2):490-492. PMID: 28082669.
Shoamanesh A, Preis SR, Beiser AS, Kase CS, Wolf PA, Vasan RS, Benjamin EJ, Seshadri S, Romero JR. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. Neurology. 2016 Sep 20; 87(12):1206-11. PMID: 27558379.
Piers RJ, Nishtala A, Preis SR, DeCarli C, Wolf PA, Benjamin EJ, Au R. Association between atrial fibrillation and volumetric magnetic resonance imaging brain measures: Framingham Offspring Study. Heart Rhythm. 2016 Oct; 13(10):2020-4. PMID: 27417740.
Bangen KJ, Himali JJ, Beiser AS, Nation DA, Libon DJ, Fox CS, Seshadri S, Wolf PA, McKee AC, Au R, Delano-Wood L. Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer’s Disease Pathology. J Alzheimers Dis. 2016 Jul 6; 53(4):1553-62. PMID: 27392855.
Nation DA, Preis SR, Beiser A, Bangen KJ, Delano-Wood L, Lamar M, Libon DJ, Seshadri S, Wolf PA, Au R. Pulse Pressure Is Associated With Early Brain Atrophy and Cognitive Decline: Modifying Effects of APOE-e4. Alzheimer Dis Assoc Disord. 2016 Jul-Sep; 30(3):210-5. PMID: 27556935.
Hankee LD, Preis SR, Piers RJ, Beiser AS, Devine SA, Liu Y, Seshadri S, Wolf PA, Au R. Population Normative Data for the CERAD Word List and Victoria Stroop Test in Younger- and Middle-Aged Adults: Cross-Sectional Analyses from the Framingham Heart Study. Exp Aging Res. 2016 Jul-Sep; 42(4):315-28. PMID: 27410241.
Qiu WQ, Himali JJ, Wolf PA, DeCarli DC, Beiser A, Au R. Effects of white matter integrity and brain volumes on late life depression in the Framingham Heart Study. Int J Geriatr Psychiatry. 2017 Feb; 32(2):214-221. PMID: 27059548.
Therkelsen KE, Preis SR, Beiser A, DeCarli C, Seshadri S, Wolf P, Au R, Fox CS. Neck Circumference, Brain Imaging Measures, and Neuropsychological Testing Measures. J Stroke Cerebrovasc Dis. 2016 Jul; 25(7):1570-81. PMID: 27056441.
Jak AJ, Preis SR, Beiser AS, Seshadri S, Wolf PA, Bondi MW, Au R. Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. J Int Neuropsychol Soc. 2016 Oct; 22(9):937-943. PMID: 27029348.
Romero JR, Preis SR, Beiser A, DeCarli C, D’Agostino RB, Wolf PA, Vasan RS, Polak JF, Seshadri S. Carotid Atherosclerosis and Cerebral Microbleeds: The Framingham Heart Study. J Am Heart Assoc. 2016 Mar 18; 5(3):e002377. PMID: 26994127.
Xing C, Huang J, Hsu YH, DeStefano AL, Heard-Costa NL, Wolf PA, Seshadri S, Kiel DP, Cupples LA, Dupuis J. Evaluation of power of the Illumina HumanOmni5M-4v1 BeadChip to detect risk variants for human complex diseases. Eur J Hum Genet. 2016 Jul; 24(7):1029-34. PMID: 26577045.